Aerosols for macromolecule delivery: Design challenges and solutions

American Journal of Drug Delivery

Volumn 2, Issue 3, 2004, Pages 143-155

  Taylor, Glyn ^a   Gumbleton, Mark ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA INTERFERON; ANTIASTHMATIC AGENT; BETA INTERFERON; CALCITONIN; CYCLOSPORIN; DIMETHYL SULFOXIDE; DORNASE ALFA; EXCIPIENT; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH HORMONE; HEPARIN; INSULIN; INTERLEUKIN 2; INTERLEUKIN 4 ANTAGONIST; LEUPRORELIN; LUNG SURFACTANT; MACROGOL; PARATHYROID HORMONE; PLASMID DNA; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE DERIVATIVE;

AEROSOL; ASTHMA; CLINICAL TRIAL; CYSTIC FIBROSIS; DENATURATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; EMPHYSEMA; GROWTH HORMONE DEFICIENCY; HEPATITIS C; HUMAN; IMMUNE DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INTERMETHOD COMPARISON; LEUKEMIA; LUNG DISEASE; LUNG METASTASIS; MACROMOLECULE; MEDICAL TECHNOLOGY; MEMBRANE PERMEABILITY; METERED DOSE INHALER; MUCOCILIARY CLEARANCE; MULTIPLE SCLEROSIS; NEBULIZER; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOPOROSIS; PARTICULATE MATTER; PHAGOCYTOSIS; POWDER INHALER; PRIORITY JOURNAL; PROSTATE CANCER; REPRODUCIBILITY; RESPIRATORY AIRFLOW; RESPIRATORY DISTRESS SYNDROME; REVIEW; SPRAY DRYING; SURFACE PROPERTY; TUBERCULOSIS;

EID: 4644232980     PISSN: 11759038     EISSN: None     Source Type: Journal    
DOI: 10.2165/00137696-200402030-00001     Document Type: Review

References (83)

1. Weibel ER. Morphometry of human lung. Berlin: Springer, 1963
2. Miller FJ, Mercer RR, Crapo JD. Lower respiratory tract structure of laboratory animals and humans: dosimetry implications. Aerosol Sci Technol 1993; 18: 257-71
3. Horsfield K, Cummings G. Morphology of the bronchial tree in man. J Appl Physiol 1968; 24:373-91
4. Yeh H, Schum GM. Models of human lung airways and their application to inhaled particle deposition. Bull Math Biol 1980; 42:461-80
5. Gehr P, Bachofen M, Weibel ER. The normal human lung: ultrastructure and morphometric estimation of diffusion capacity. Respir Physiol 1978; 32: 121-40
6. Bastacky J, Lee CY, Goerke J, et al. Alveolar lining layer is thin and continuous: low temperature scanning electron microscopy of rat lung. J Appl Physiol 1995; 7: 1615-28
7. Crapo JD, Barry BE, Gehr P, et al. Cell number and cell characteristics of normal human lung. Am Rev Respir Dis 1983; 125: 332-7
8. Colthorpe P, Farr SJ, Taylor G, et al. The pharmacokinetics of pulmonary delivered insulin: a comparison of intra-tracheal and aerosol administration to the rabbit. Pharm Res 1992; 9: 765-8
9. Colthorpe P, Farr SJ, Smith IJ, et al. The influence of regional deposition on the pharmacokinetics of pulmonary-delivered human growth hormone in rabbits. Pharm Res 1995; 12: 356-9
10. Heubner W, de Jough SE, Laquer E. Uber inhalation von insulin. Klin Wochenschr 1924; 3: 2342-3
11. Gänsslen M. Uber inhalation von insulin. Klin Wochenschr 1925; 4: 71-2
12. Effros RM, Mason GR. Measurements of pulmonary epithelial permeability in vivo. Am Rev Respir Dis 1983; 127: S59-65
13. Schanker LS, Hemberger JA. Relation between molecular weight and pulmonary absorption rate of lipid-insoluble compounds in neonatal and adult rats. Biochem Pharmacol 1983; 32: 2599-601
14. Schanker LS, Mitchell EW, Brown RA. Species comparison of drug absorption from the lung after aerosol inhalation or intratracheal injection. Drug Metab Dispos 1986; 14: 79-88
15. Folkesson HG, Westrom BR, Karlsson BW. Permeability of the respiratory tract to different-sized macromolecules after intratracheal instillation in young and adult rats. Acta Physiol Scand 1990; 139: 347-54
16. Wall DA. Pulmonary absorption of peptides and proteins. Drug Deliv 1995; 2: 1-20
17. Yu J, Chien YW. Pulmonary drug delivery: physiologic and mechanistic aspects. Crit Rev Ther Drug Carrier Syst 1997; 14: 395-453
18. Patton JS. Breathing life into protein drugs. Nat Biotechnol 1998; 16: 141-3
19. Byron PR, Patton JS. Drug delivery via the respiratory tract. J Aerosol Med 1994; 7: 49-75
20. Adjei AL, Gupta PK, editors. Inhalation delivery of therapeutic peptides and proteins. New York: Marcel Dekker Inc., 1997
21. Patton JS. Mechanisms of macromolecule absorption by the lungs. Adv Drug Deliv Rev 1996; 19: 3-36
22. Gumbleton M. Caveolae as potential macromolecule trafficking compartments within alveolar epithelium. Adv Drug Deliv Rev 2001; 49: 281-300
23. Taylor G, Colthorpe P, Farr SJ. Pulmonary absorption of proteins: influence of deposition site and competitive elimination processes. In: Dalby RN, Byron PR, Peart J, et al., editors. Respiratory drug delivery IV. Buffalo Grove (IL): Interpharm Press, 1994: 25-37
24. Hubbard RC. Alpha-I antitrypsin. In: Adjei AL, Gupta PK, editors. Inhalation delivery of therapeutic peptides and proteins. New York: Marcel Dekker Inc., 1997:315-30
25. Vogelmeier C, Kirlath I, Warrington S, et al. The intrapulmonary half-life and safety of aerosolized alphal-protease inhibitor in normal volunteers. Am J Respir Crit Care Med 1997; 155: 536-41
26. Kropp J, Wencker M, Hotze A, et al. Inhalation of [123I]alpha 1-protease inhibitor: toward a new therapeutic concept of alphal-protease inhibitor deficiency? J Nucl Med 2001; 42: 744-51
27. Flament MP, Leterme P, Gayot A. Influence of the technological parameters of ultrasonic nebulisation on the nebulisation quality of alphal protease inhibitor (alpha1PI). Int J Pharm 1999; 189: 197-204
28. Allen ED. Opportunities for the use of aerosolized alpha 1-antitrypsin for the treatment of cystic fibrosis. Chest 1996; 110: 256S-60S
29. Gonda I. Deoxyribonuclease inhalation. In: Adjei AL, Gupta PK, editors. Inhalation delivery of therapeutic peptides and proteins. New York: Marcel Dekker Inc., 1997: 355-65
30. Robinson PJ. Dornase alfa in early cystic fibrosis lung disease. Pediatr Pulmonol 2002; 34: 237-41
31. Driskell RA, Engelhardt JF. Current status of gene therapy for inherited lung diseases. Annu Rev Physiol 2003; 65: 585-612
32. Ferrari S, Geddes DM, Alton EW. Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis. Adv Drug Deliv Rev 2002; 54: 1373-93
33. Birchall JC, Kellaway IW, Gumbleton M. Physical stability and in-vitro gene expression efficiency of nebulised lipid-peptide-DNA complexes. Int J Pharm 2000; 197: 221-31
34. Crook K, McLachlan G, Stevenson BJ, et al. Plasmid DNA molecules complexed with cationic liposomes are protected from degradation by nucleases and shearing by aerosolisation. Gene Ther 1996; 3: 834-9
35. Rudolph C, Muller RH, Rosenecker J. Jet nebulization of PEI/DNA polyplexes: physical stability and in vitro gene delivery efficiency. J Gene Med 2002; 4: 66-74
36. Seville PC, Kellaway IW, Birchall JC. Preparation of dry powder dispersions for non-viral gene delivery by freeze-drying and spray-drying. J Gene Med 2002; 4: 428-37
37. Deshpande D, Blanchard J, Srinivasan S, et al. Aerosolization of lipoplexes using AERx pulmonary delivery system [abstract] AAPS PharmSci 2002; 4: E13
38. Farr S J, Taylor G. Insulin inhalation. In: Adjei AL, Gupta PK, editors. Inhalation delivery of therapeutic peptides and proteins. New York: Marcel Dekker Inc., 1997: 371-87
39. Patton JS, Bukar J, Nagarajan S. Inhaled insulin. Adv Drug Deliv Rev 1999; 35: 235-47
40. Farr S, Reynolds D, Nat A, et al. Technical development of AERx diabetes management system: essential characteristics for diabetes treatment with pulmonary insulin. In: Dalby RN, Byron PR, Peart J, et al., editors. Respiratory drug delivery VIII. Raleigh (NC): Davis Horwood International Publishing, 2002: 51-9
41. Niven RW. Feasibility studies with recombinant human granulocyte colony-stimulating factor. In: Adjei AL, Gupta PK, editors. Inhalation delivery of therapeutic peptides and proteins. New York: Marcel Dekker Inc., 1997: 413-52
42. Niven RW, Ip AY, Mittelman SD, et al. Protein nebulization: I. Stability of lactate dehydrogenase and recombinant granulocyte-colony stimulating factor to air-jet nebulization, Int J Pharm 1994; 109: 17-26
43. Niven RW, Prestrelski SJ, Treuheit MJ, et al. Protein nebulization: II. Stabilization of G-CSF to air-jet nebulization and the role of protectants. Int J Pharm 1996; 1127: 191-201
44. Adjei AL, Lu MYF. LH-RH Analogs. In: Adjei AL, Gupta PK, editors. Inhalation delivery of therapeutic peptides and proteins. New York: Marcel Dekker Inc., 1997: 389-412
45. Ma YF, Nguyen PA, Andya JD, et al. Effect of spray-drying and subsequent processing conditions on residual moisture content and physical/biochemical stability of protein inhalation powders. Pharm Res 1998; 15: 768-75
46. Chan HK, Clark A, Gonda I, et al. Spray-dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery. Pharm Res 1997; 14: 431-7
47. Phillips E, Allsopp E, Christensen T, et al. Size reduction of peptides and proteins by jet-milling. In: Dalby RN, Byron PR, Farr SJ, editors. Respiratory drug delivery VI. Buffalo Grove (IL): Interpharm Press, 1998: 161-8
48. LiCalsi C, Maniaci MJ, Christensen T, et al. A powder formulation of measles vaccine for aerosol delivery. Vaccine 2001; 19: 2629-36
49. Hardy JG, Crew P, Osborne P, et al. Clinical evaluation of inhaled insulin stabilized with trehalose. In: Dalby RN, Byron PR, Peart J, et al., editors. Respiratory drug delivery VIII. Raleigh (NC): Davis Horwood International Publishing, 2002: 415-7
50. Ma YF, Nguyen PA, Hsu SW. Spray-drying of air-liquid interface sensitive recombinant human growth hormone. J Pharm Sci 1998; 87: 152-9
51. Vanbever R, Mintzes JD, Wang J, et al. Formulation and physical characterization of large porous particles for inhalation. Pharm Res 1999; 16: 1735-42
52. 2-assisted aerosolization. J Pharm Sci 2001; 90: 785-97
53. Moshashaee S, Bisrat M, Forbes RT, et al. Supercritical fluid processing of proteins: lysozyme precipitation from aqueous solution. J Pharm Pharmacol 2003; 55: 185-92
54. Bustami RT, Chan HK, Dehghani F, et al. Generation of micro-particles of proteins for aerosol delivery using high pressure modified carbon dioxide. Pharm Res 2000; 17: 1360-6
55. Brown LR, Rasbba-Step J, Scott T, et al. Pulmonary delivery of novel insulin microspheres. In: Dalby RN, Byron PR, Peart J, et al., editors. Respiratory drug delivery VIII. Raleigh (NC): Davis Horwood International Publishing, 2002: 431-3
56. Bhat MG, Hughes ML, Dobbins MA, et al. Development of a novel spray-drying technique to produce particles for aerosol delivery. In: Dalby RN, Byron PR, Peart J, et al., editors. Respiratory drug delivery VIII. Raleigh (NC): Davis Horwood International Publishing, 2002: 427-9
57. Blair J, Coghlan D, Langner E, et al. Sustained delivery of insulin via the lung using Solidose technology. In: Dalby RN, Byron PR, Peart J, et al., editors. Respiratory drug delivery VIII. Raleigh (NC): Davis Horwood International Publishing, 2002: 411-3
58. Davidson IG, Langner EJ, Plowman SV, et al. Release mechanism of insulin encapsulated in trehalose ester derivative microparticles delivered via inhalation. Int J Pharm 2003; 254: 211-22
59. Alcock R, Blair JA, O'Mahony DJ, et al. Modifying the release of leuprolide from spray dried OED microparticles. J Control Release 2002; 82: 429-40
60. Niven RW, Byron PR. Solute absorption from the airways of the isolated rat lung: II. Effect of surfactants on absorption of fluorescein. Pharm Res 1990; 7: 8-13
61. Kobayashi S, Kondo S, Juni K. Study on pulmonary delivery of salmon calcitonin in rats: effects of protease inhibitors and absorption enhancers. Pharm Res 1994; 11: 1239-43
62. Yamamoto A, Umemori S, Muranishi S. Absorption enhancement of intrapulmonary administered insulin by various absorption enhancers and protease inhibitors in rats. J Pharm Pharmacol 1994; 46: 14-8
63. Pfutzner A, Mann AE, Steiner SS. Technosphere/insulin: a new approach for effective delivery of human insulin via the pulmonary route. Diabetes Technol Ther 2002; 4: 589-94
64. Pfutzner A, Flacke F, Pohl R, et al. Pilot study with Technosphere/PTH (1-34): a new approach for effective pulmonary delivery of parathyroid hormone (1-34). Horm Metab Res 2003; 35: 319-23
65. Farr SJ, Rowe AM, Rubsamen R, et al. Aerosol deposition in the human lung following administration from a microprocessor-controlled pressurised metered dose inhaler. Thorax 1995; 50: 639-44
66. Thipphawong J, Otulana B, Clauson P, et al. Pulmonary insulin administration using the AERx insulin diabetes system. Diabetes Technol Ther 2002; 4: 499-504
67. Lee SW, Sciarra JJ. Development of an aerosol dosage form containing insulin. J Pharm Sci 1976; 65: 567-73
68. Oliver MJ, McKenzie L, Pritchard Y. Evaluation of pressurised metered dose inhalers for pulmonary delivery of proteins and peptides [abstract]. J Aerosol Med 2001; 14: 394
69. Cefalu WT, Skyler JS, Kourides IA, et al. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med 2001; 134: 203-7
70. Skyler JS, Cefalu WT, Kourides IA, et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomized proof-of-concept study. Lancet 2001; 357: 331-5
71. Cappelleri JG, Cefalu WT, Rosenstock J, et al. Treatment satisfaction in type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous insulin regimen. Clin Ther 2002; 24: 552-64
72. Densmore CL, Gautam A, Waldrep JC, et al. Re-establishing gene therapy by aerosol using transfection-efficient, low toxicity DNA-polymer constructs. In: Dalby RN, Byron PR, Peart J, et al, editors. Respiratory drug delivery VIII. Raleigh (NC): Davis Horwood International Publishing, 2002: 25-32
73. Khatri L, Taylor KM, Craig DQ, et al. An assessment of jet and ultrasonic nebulisers for the delivery of lactate dehydrogenase solutions. Int J Pharm 2001; 227: 121-31
74. Kastelik JA, Wright GA, Aziz I, et al. A widely available method for the assessment of aerosol delivery in cystic fibrosis. Pulm Pharmacol Ther 2002; 15: 513-9
75. Schuster J, Rubsamen R, Lloyd P, et al. The AERx aerosol delivery system. Pharm Res 1997; 14: 354-7
76. Mudumba S, Wu H, Ta S, et al. Development of the interferon gamma-1b (IFN-γ 1b)-AERx system [abstract]. J Aerosol Med 2003; 16: 189
77. Sangwan S, Agosti JM, Bauer LA, et al. Aerosolized protein delivery in asthma: gamma camera analysis of regional deposition and perfusion. J Aerosol Med 2001; 14: 185-95
78. Geller D, Thipphawong J, Otulana B, et al. Bolus inhalation of rhDNase with the AERx system in subjects with cystic fibrosis. J Aerosol Med 2003; 16: 175-82
79. Perera AD, Kapitza C, Nosek L, et al. Absorption and metabolic effect of inhaled insulin: intrapatient variability after inhalation via the Aerodose insulin inhaler in patients with type 2 diabetes. Diabetes Care 2002; 12: 2276-81
80. Smart J, Stangl R, Fritz E. TouchSpray technology: a preliminary in vitro evaluation of plasmid DNA of different size and topology. In: Dalby RN, Byron PR, Peart J, et al., editors. Respiratory drug delivery VIII. Raleigh (NC): Davis Horwood International Publishing, 2002: 529-31
81. Goodall S, Chew N, Chan K, et al. Aerosolization of protein solutions using thermal inkjet technology. J Aerosol Med 2002; 15: 351-7
82. Edwards DA, Dunbar C. Bioengineering of therapeutic aerosols. Annu Rev Biomed Eng 2002; 4: 93-7
83. Chew NY, Chan HK. The role of particle properties in pharmaceutical powder inhalation formulations. J Aerosol Med 2002; 15: 325-30